Upstart CTO and CFO to Participate in Fireside Chat at the BofA Securities 2025 Global Technology Conference
SAN MATEO, Calif.--(BUSINESS WIRE)--Upstart Holdings, Inc. (NASDAQ: UPST), the leading artificial intelligence (AI) lending marketplace, today announced that Paul Gu, Co-founder and Chief Technology Officer, and Sanjay Datta, Chief Financial Officer, will participate in a fireside chat at the BofA Securities 2025 Global Technology Conference on Tuesday, June 3 at 10:40am PT (1:40pm ET).
A live audio webcast of the event will be available on Upstart's investor relations website at ir.upstart.com. A replay of the webcast will be available for a limited period of time following the event.
About Upstart
Upstart (NASDAQ: UPST) is the leading AI lending marketplace, connecting millions of consumers to more than 100 banks and credit unions that leverage Upstart's AI models and cloud applications to deliver superior credit products. With Upstart AI, lenders can approve more borrowers at lower rates while delivering the exceptional digital-first experience customers demand. More than 90% of loans are fully automated, with no human intervention by Upstart. Founded in 2012, Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar 'relief' loans. Upstart is based in San Mateo, California.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Treasury Options Skew June 2025
Implied volatility in options on Treasury futures has drifted lower since April, but the skew—particularly in the belly of the curve—remains a focal point. As traders prepare for a data-heavy June, including Non-Farm Payrolls, CPI and the FOMC, the behavior of skew and CVOL in the Ultra 10-Year (UXY) futures complex offers a revealing lens into how rate risk is being priced. Downside skew in Treasury options—especially on 5-Year (FV), 10-Year (TY) and Ultra 10-Year (UXY) futures—remains elevated. TYVY, the CVOL Index for 10-Year Treasury options, has declined from April highs but is still holding in the 115–120 range. Key macro events ahead: Non-Farm Payrolls – Friday, June 6 . Consumer Price Index (CPI) – Wednesday, June 12. FOMC Statement – Wednesday, June 18, 2:00 p.m. ET; press conference at 2:30 p.m. ET. PCE Price Index – Friday, June 27. Despite the decline in overall volatility, downside skew remains persistent, particularly in UXY and FV options. Traders continue to assign higher premiums to puts relative to calls, reflecting structural demand for downside hedges or latent concerns about fiscal risk, policy missteps or supply shocks. As we approach the June 6 jobs report, and especially the June 18 FOMC decision, this skew could be tested. Traders can use CVOL to see TVL or volatility indices for 2-, 5-, 10-Year and Bond futures. For volatility on options like the growing option volume on Ultra 10-Year futures consider QuikVol's QuikSkew analytics. The 2s10s curve steepened in May, reviving interest in conditional curve trades using options to express directional views on curve shape. Options are increasingly being used to express conditional curve trades. Call spreads in FV versus put spreads in UXY. Butterfly structures around inflection points in UXY to capture steepening potential without excessive Vega exposure. TYVY skew, built on deep liquidity from options on 10-Year Note futures, supports this theme. Depending on one's risk management strategy, options on 10-Year Note futures or options on Ultra 10-Year futures retain more downside premium relative to other tenors. We have expanded our suite of Treasury options with the addition of Tuesday and Thursday expiries, significantly enhancing the flexibility of short-dated hedging strategies. This update allows market participants to position tactically around high-impact economic releases such as Non-Farm Payrolls, CPI and FOMC decisions, by accessing expiries available every trading day of the week, two weeks forward. This enhancement is especially valuable in environments with compressed risk windows, intraday volatility bursts, or when event timing doesn't align neatly with the traditional Monday/Wednesday/Friday expiration schedule. The change was detailed in CME Group SER-9566R. With the macro spotlight on June 6 and June 18, options on Treasury futures offer deep insight into how rate risk is being repriced. Skews in UXY options, the behavior of TVL and renewed activity in curve-based option structures all point to a market that sees risk beneath the surface. Whether you're watching TVL or the new Tuesday and Thursday expiries, June will be a month to track the message inside the vol surface. All examples in this report are hypothetical interpretations of situations and are used for explanation purposes only. The views in this report reflect solely those of the author and not necessarily those of CME Group or its affiliated institutions. This report and the information herein should not be considered investment advice or the results of actual market experience. Derivatives are not suitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell or retain any specific investment or service. All examples in this report are hypothetical interpretations of situations and are used for explanation purposes only. The views in this report reflect solely those of the author and not necessarily those of CME Group or its affiliated institutions. This report and the information herein should not be considered investment advice or the results of actual market experience. CME Group Inc. does not have control over the content, accuracy, quality, or legality, of any third-party product, service, or content advertised on this webpage. The presence of such advertisements on this webpage does not signify any association, partnership, or endorsement of the third-party or its content by CME Group Inc. Full disclaimer Copyright © 2025 CME Group Inc.
Yahoo
2 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
